Journal profile · Medicine-Health Policy
Farmakoekonomika
ISSN 2070-4909 · eISSN 2070-4933 · IRBIS LLC · Russian Federation
Farmakoekonomika: impact factor 0.33 (journal website); fully open access; APC charged, amount not published; review about 8 weeks (community reports); 49 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Farmakoekonomika is published by IRBIS LLC. By OpenAlex counts of its recent articles, its largest topics are Healthcare Systems and Public Health, Health Systems, Economic Evaluations, Quality of Life and Pharmaceutical Economics and Policy, together about 38.5% of its articles. Its main subfields are Economics and Econometrics. (generated from OpenAlex topic counts and CAS ranking data)
The main goal of the journal is to publish high-quality original articles, scientific reviews, and the best practical examples in the area of health economics and outcomes research (HEOR) as well as pharmacoepidemiology. Our priorities focus on scientific and information support to the decision-makers and experts in public drug supply, health providers, research and education professionals, as well as pharmaceutic and insurance companies. Among the peer-reviewed journals in this field, this journal is considered the first and most reputable in Russia and the EurAsEC (Eurasian Economic Community) countries. As an open-access journal, «FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology» is available in the Russian Federation and around the world. The editorial board includes 8 internationally known scientists, 2 full members of the Russian Academy of Sciences (RAS), and 7 corresponding members of the RAS. The editorial board promotes the policy of full compliance with the principles of international scientific publishing ethics. All submitted materials undergo a compulsory double-blind peer reviewing process.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Health Policy
Editor-in-chief Vitaly V. OmelyanovskiyPublisher website
Editorial board by country: none in mainland China; most named Russia 30, Spain 2, United States 1, United Kingdom 1, Israel 1 (35 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Healthcare Systems and Public HealthMedicine16.6%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance12.1%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance9.8%
- Economic, Social, and Public Health Issues in Russia and GloballyDecision Sciences6.2%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance4.4%
- Artificial Intelligence in Healthcare and EducationMedicine3.5%
- Respiratory and Cough-Related ResearchMedicine3.5%
- Human Health and DiseaseMedicine3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 0.33Publisher website ·
- CiteScore 2026-06
- 1.2LetPub ·
- SJR 2026-06
- 0.16LetPub ·
- SNIP 2026-06
- 0.48LetPub ·
- h-index
- 15OpenAlex ·
- i10-index
- 31OpenAlex ·
- 2-year mean citedness
- 1.15OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 509 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 54 | 54 | 16 |
| 2025 | 49 | 49 | 72 |
| 2024 | 45 | 45 | 82 |
| 2023 | 65 | 65 | 157 |
| 2022 | 43 | 43 | 159 |
| 2021 | 46 | 46 | 275 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | RUB 15,000 | No | CC BY-NC-SA | |
| OpenAlex | RUB 15,000 | — | — | |
| LetPub | RUB 15,000 | No | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≤ 8
- Reference style
- Numbered, in order of citation
- Cover letter
- Required
Article types accepted2
- original articleEstimation of the socio-economic burden of obesity in the Russian Federation L. Yu. Gorbachenko, K. I. Matrenin, A. A. Slabikova, R. A. Teryan, D. N. Pustovalov…Length not stated
- review articleMethodology approach to developing criteria for selecting hemophilia drugs included in the High-Cost Nosology program A. G. Kharitonova, V. V. Omelyanovskiy, K.…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Plagiarism, Preprints
- AI use Policy on the use of artificial intelligence tools
Authors who use artificial intelligence (AI) tools including large language or graph models (neural networks) such as ChatGPT, DALL-E 2, Midjourney etc. in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, must be transparent in disclosing in the Materials and Methods of the paper how the AI tool was used, and which AI …
Source ↗Publisher website ·- Authorship The position in relation to the authorship
Based on ICMJE recommendations and [McNutt et al., Proceedings of National Academy of Sciences, Feb 2018, 201715374; DOI: 10.1073 / pnas.1715374115; лицензировано в соответствии с CC BY 4.0] All members of the group of authors should meet all four criteria of authorship set forth in the ICMJE recommendations: 1) concept and design development or data analysis and interpretation2) manuscript justif…
Source ↗Publisher website ·- Conflicts of interest Disclosure and Conflict of Interest
Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborat…
Source ↗Publisher website ·- Data availability Clinical trials data sharing policy
According to the latest recommendations of the ICMJE, when submitting an article containing data on a clinical study, the authors should submit a separate document "Statement on data sharing". In accordance with statement of the International Committee of Medical Journal Editors, as of July 1, 2018, manuscripts submitted to the journal that report the results of clinical trials must contain a data…
Source ↗Publisher website ·- License & copyright Copyright Notice
Creative Commons Attribution License for published work. Model summary
Authors who publish with this journal agree to the following terms: Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrang…
Source ↗Publisher website ·- Open access Open Access Policy
It is an open access journal. All articles are made freely available to readers immediatly upon publication. Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition - it means that articles have free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, cr…
Source ↗Publisher website ·- Peer review Peer-Review
Double-blind peer review Model summary
A double-blind peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of "FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology". This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer. Members of the editorial board and leading Russian and inter…
Source ↗Publisher website ·- Plagiarism Plagiarism detection
"FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology" use native russian-language plagiarism detection software Antiplagiat to screen the submissions. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.
Source ↗Publisher website ·- Preprints Preprint and postprint Policy
Prior to acceptance and publication in "FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology", authors may make their submissions available as preprints on personal or public websites. As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in "FARMAKOEKONOMIKA…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- IRBIS LLC
- Country or region
- Russian Federation
- Language
- Russian
- ISSN
- 2070-4909
- Electronic ISSN
- 2070-4933
- Latest issue on the website
- Volume 19, Issue 2 (2026)
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Farmakoekonomika
What is the impact factor of Farmakoekonomika?
The journal's website gives an impact factor of 0.33; this is the journal's own figure, as LetPub lists none for it; CiteScore 1.2, h-index 15.
How long does peer review take at Farmakoekonomika?
Authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Farmakoekonomika?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≤ 8; Reference style: Numbered, in order of citation; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Farmakoekonomika based?
Of the 35 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Russia (30), Spain (2) and United States (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Farmakoekonomika?
According to LetPub and DOAJ records, Farmakoekonomika is indexed in Scopus and DOAJ.
Is Farmakoekonomika open access, and what is the APC?
Farmakoekonomika is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .